CN113382714A - 胶原酶制剂及其制备方法 - Google Patents

胶原酶制剂及其制备方法 Download PDF

Info

Publication number
CN113382714A
CN113382714A CN202080010875.3A CN202080010875A CN113382714A CN 113382714 A CN113382714 A CN 113382714A CN 202080010875 A CN202080010875 A CN 202080010875A CN 113382714 A CN113382714 A CN 113382714A
Authority
CN
China
Prior art keywords
formulation
collagenase
freeze
dried
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080010875.3A
Other languages
English (en)
Chinese (zh)
Inventor
K·苏库鲁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paladin Pharmaceutical Co
Endo Operations Ltd
Original Assignee
Endo Global Aesthetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Global Aesthetics Ltd filed Critical Endo Global Aesthetics Ltd
Publication of CN113382714A publication Critical patent/CN113382714A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202080010875.3A 2019-01-06 2020-01-03 胶原酶制剂及其制备方法 Pending CN113382714A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788916P 2019-01-06 2019-01-06
US62/788,916 2019-01-06
PCT/US2020/012202 WO2020142701A1 (en) 2019-01-06 2020-01-03 Collagenase formulations and methods of producing the same

Publications (1)

Publication Number Publication Date
CN113382714A true CN113382714A (zh) 2021-09-10

Family

ID=69845512

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080010875.3A Pending CN113382714A (zh) 2019-01-06 2020-01-03 胶原酶制剂及其制备方法

Country Status (10)

Country Link
US (3) US20220305094A1 (https=)
EP (1) EP3906014A1 (https=)
JP (2) JP7565280B2 (https=)
KR (1) KR20210113271A (https=)
CN (1) CN113382714A (https=)
AU (2) AU2020204922B2 (https=)
BR (1) BR112021012675A2 (https=)
IL (2) IL321891A (https=)
MX (1) MX2021008017A (https=)
WO (1) WO2020142701A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113025599A (zh) * 2021-04-02 2021-06-25 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
CN114264633A (zh) * 2022-02-10 2022-04-01 上海蓝长科技集团有限公司 一种福尔马肼聚合物冻干粉及制备方法
CN119656117A (zh) * 2024-12-18 2025-03-21 远大生命科学(鞍山)有限公司 一种药物组合物及其制备方法和用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112941058B (zh) * 2021-04-02 2023-12-05 重庆科润生物医药研发有限公司 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用
AU2023232693A1 (en) * 2022-03-08 2024-09-19 Connext Co.,Ltd. Composition comprising collagenase, calcium, histidine, and glycine, and method for stabilizing collagenase

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100675A2 (en) * 2006-02-22 2007-09-07 The Research Foundation Of The State University Of New York Collagenase for treating cellulite
CN101209347A (zh) * 1999-10-01 2008-07-02 安姆根有限公司 纤维蛋白溶解剂药用组合物
CN101312744A (zh) * 2005-11-22 2008-11-26 惠氏公司 免疫球蛋白融合蛋白制剂
CN101684461A (zh) * 2008-06-02 2010-03-31 霍夫曼-拉罗奇有限公司 改进的从溶组织梭菌液体培养物纯化胶原酶
WO2013059619A1 (en) * 2011-10-21 2013-04-25 Auxilium Pharmaceuticals, Inc. Method of treating or reducing efp
US20180099049A1 (en) * 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Room Temperature Stable Lyophilized Protein
WO2018160905A1 (en) * 2017-03-01 2018-09-07 Endo Ventures Limited Apparatus and method for assessing and treating cellulite

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2921180B1 (en) * 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2012125948A1 (en) 2011-03-16 2012-09-20 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
PT2802652T (pt) 2012-01-12 2019-09-10 Endo Global Ventures Enzimas de clostridium histolyticum
EP3834840B8 (en) 2013-03-15 2025-09-17 Endo Biologics Limited Treatment method and product for uterine fibroids using purified collagenase
US10137179B2 (en) * 2016-05-18 2018-11-27 Hyalo Technologies, LLC Composition and method of preparation of protease microparticulate slow release preparation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209347A (zh) * 1999-10-01 2008-07-02 安姆根有限公司 纤维蛋白溶解剂药用组合物
CN101312744A (zh) * 2005-11-22 2008-11-26 惠氏公司 免疫球蛋白融合蛋白制剂
WO2007100675A2 (en) * 2006-02-22 2007-09-07 The Research Foundation Of The State University Of New York Collagenase for treating cellulite
CN101684461A (zh) * 2008-06-02 2010-03-31 霍夫曼-拉罗奇有限公司 改进的从溶组织梭菌液体培养物纯化胶原酶
WO2013059619A1 (en) * 2011-10-21 2013-04-25 Auxilium Pharmaceuticals, Inc. Method of treating or reducing efp
US20180099049A1 (en) * 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Room Temperature Stable Lyophilized Protein
WO2018160905A1 (en) * 2017-03-01 2018-09-07 Endo Ventures Limited Apparatus and method for assessing and treating cellulite

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113025599A (zh) * 2021-04-02 2021-06-25 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
CN113025599B (zh) * 2021-04-02 2023-09-12 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
CN114264633A (zh) * 2022-02-10 2022-04-01 上海蓝长科技集团有限公司 一种福尔马肼聚合物冻干粉及制备方法
CN119656117A (zh) * 2024-12-18 2025-03-21 远大生命科学(鞍山)有限公司 一种药物组合物及其制备方法和用途
CN119656117B (zh) * 2024-12-18 2025-08-29 远大生命科学(鞍山)有限公司 一种药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
JP2022516569A (ja) 2022-02-28
IL321891A (en) 2025-09-01
AU2025204915A1 (en) 2025-07-24
AU2020204922B2 (en) 2025-04-24
IL284270A (en) 2021-08-31
JP7565280B2 (ja) 2024-10-10
MX2021008017A (es) 2021-08-05
JP2025016453A (ja) 2025-02-04
BR112021012675A2 (pt) 2021-09-28
CA3125007A1 (en) 2020-07-09
US20250249080A1 (en) 2025-08-07
WO2020142701A1 (en) 2020-07-09
US20240041993A1 (en) 2024-02-08
US20220305094A1 (en) 2022-09-29
IL284270B1 (en) 2025-08-01
US12303557B2 (en) 2025-05-20
KR20210113271A (ko) 2021-09-15
AU2020204922A1 (en) 2021-07-01
EP3906014A1 (en) 2021-11-10
IL284270B2 (en) 2025-12-01

Similar Documents

Publication Publication Date Title
CN113382714A (zh) 胶原酶制剂及其制备方法
Haeuser et al. Excipients for room temperature stable freeze-dried monoclonal antibody formulations
BRPI0711635A2 (pt) formulação de vacina de nicotina-veìculo
JP6226966B2 (ja) デガレリクスの製造
CN112516090B (zh) 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
AU2021250949A1 (en) Liquid Pharmaceutical Composition
CN108379561B (zh) 一种聚乙二醇化尿酸氧化酶冻干粉剂及其制备方法
HK40053714A (en) Collagenase formulations and methods of producing the same
WO2018184540A1 (zh) 包含组氨酸缓冲体系的英夫利西单抗组合物
CA2900114A1 (en) Stable nocathiacin lyophilized injection agent
KR20260025359A (ko) 다클론 IgM을 포함하는 동결건조 조성물을 생산하는 방법 및 수득된 조성물
KR20260051486A (ko) 콜라게나제 제형 및 이의 제조 방법
Vargas et al. Formulation development and feasibility of AAV5 as a lyophilized drug product
CA3125007C (en) Collagenase formulations and methods of producing the same
CN115998690B (zh) 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
HK40087140A (zh) 组织纤溶酶原激活剂制剂
DK202570004A1 (en) Clostridium botulinum neurotoxin serotype a compositions and improved drying processes
KR20230047124A (ko) 조직 플라스미노겐 활성인자 제형

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053714

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240805

Address after: Ai Erlandubailin

Applicant after: Endo Operations Co.,Ltd.

Country or region after: Ireland

Address before: Saint Laurent, Canada

Applicant before: Paladin Pharmaceutical Co.

Country or region before: Canada

Effective date of registration: 20240805

Address after: Saint Laurent, Canada

Applicant after: Paladin Pharmaceutical Co.

Country or region after: Canada

Address before: Ai Erlandubailin

Applicant before: Endo global aesthetics Ltd.

Country or region before: Ireland